Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Buy” by Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has received a consensus rating of “Buy” from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $22.90.

Several brokerages recently weighed in on CMPS. B. Riley Financial began coverage on Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 price target for the company. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. HC Wainwright reissued a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Wolfe Research started coverage on Compass Pathways in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Finally, UBS Group set a $18.00 target price on Compass Pathways in a report on Thursday, May 7th.

Compass Pathways Price Performance

Shares of NASDAQ CMPS opened at $12.63 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The stock has a fifty day moving average price of $10.36 and a 200 day moving average price of $7.91. Compass Pathways has a 1-year low of $2.25 and a 1-year high of $14.76. The company has a market cap of $1.70 billion, a PE ratio of -4.01 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Sell-side analysts forecast that Compass Pathways will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Compass Pathways

Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its holdings in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after acquiring an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Compass Pathways in the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Compass Pathways in the fourth quarter valued at $47,000. Advisory Services Network LLC acquired a new stake in Compass Pathways in the third quarter valued at $41,000. Finally, Parallel Advisors LLC raised its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.